Luk Vandenberghe
Founder at Affinia Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ed Mathers Mathers | M | 64 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Carole Faig | F | 62 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Rick Modi | M | 55 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
David Scadden | M | 71 |
Harvard Medical School
| - |
Sean Nolan | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 5 years |
Caroline Stout | F | 33 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 3 years |
Dave Grayzel | M | 56 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Merit Cudkowicz | M | 61 |
Harvard Medical School
| - |
Scott Dorfman | M | 66 |
Odylia Therapeutics
| 7 years |
Charles Sigal | M | 72 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | 4 years |
Christine Seidman | M | 71 |
Harvard Medical School
| 27 years |
Claus Cursiefen | M | - |
Harvard Medical School
| - |
Alexander G. Marneros | M | - |
Harvard Medical School
| - |
Atul Gawande | M | 58 |
Harvard Medical School
| - |
Jeffrey Flier | M | 76 |
Harvard Medical School
| 17 years |
Vijay Kumar Kuchroo | M | 69 |
Harvard Medical School
| - |
Bruce E. Johnson | M | - |
Harvard Medical School
| - |
Kasper Lage | M | - |
Harvard Medical School
| - |
Laurence Rahme | M | - |
Harvard Medical School
| - |
Keith Flaherty | M | 53 |
Harvard Medical School
| 15 years |
Peter Sorger | M | - |
Harvard Medical School
| - |
Xun Zhang | M | 62 |
Harvard Medical School
| 21 years |
Utkan Demirci | M | - |
Harvard Medical School
| - |
Marlene Freeman | F | - |
Harvard Medical School
| - |
Rudolph Emile Tanzi | M | - |
Harvard Medical School
| - |
Paul G. Richardson | M | - |
Harvard Medical School
| - |
David Weiner | M | - |
Harvard Medical School
| - |
Alexandra Kimball | M | - |
Harvard Medical School
| - |
G. Gilbert | M | 82 |
Harvard Medical School
| - |
Deepak Bhatt | M | 56 |
Harvard Medical School
| - |
Monica Bertagnolli | M | 65 |
Harvard Medical School
| - |
Allan Formicola | M | - |
Harvard Medical School
| - |
Jeanne Ackman | F | - |
Harvard Medical School
| - |
Martha Crowninshield | F | - |
Harvard Medical School
| - |
Matt Tyson-Durno | M | - |
Harvard Medical School
| - |
Shaké Sulikyan | F | - |
Harvard Medical School
| - |
Missy Carter | F | - |
Harvard Medical School
| - |
Emery Brown | M | 67 |
Harvard Medical School
| - |
Harold J Burstein | M | - |
Harvard Medical School
| - |
Marcela Maus | M | 48 |
Harvard Medical School
| - |
Roy Freeman | M | 72 |
Harvard Medical School
| - |
Ole Isacson | M | 64 |
Harvard Medical School
| 22 years |
Paula D. Polito | F | 64 |
Harvard Medical School
| - |
Michael J. McKenna | M | 67 |
Harvard Medical School
| 28 years |
Isaac Kohane | M | 64 |
Harvard Medical School
| 16 years |
H. Franklin Bunn | M | - |
Harvard Medical School
| - |
Beverly M.K. Biller | M | - |
Harvard Medical School
| - |
Ramnik Xavier | M | 62 |
Harvard Medical School
| 11 years |
Michael C. Gibson | M | - |
Harvard Medical School
| 37 years |
Howard Weiner | M | 78 |
Harvard Medical School
| - |
William R. Sellers | M | 63 |
Harvard Medical School
| - |
Mark Barry Abelson | M | - |
Harvard Medical School
| - |
John W. Winkelman | M | - |
Harvard Medical School
| - |
Roderick K. King | M | - |
Harvard Medical School
| - |
John Halpern | M | - |
Harvard Medical School
| - |
Barbara McNeil | M | 83 |
Harvard Medical School
| 41 years |
William Kaelin | M | 66 |
Harvard Medical School
| 22 years |
N. Coles | M | 63 |
Harvard Medical School
| - |
John Halamka | M | 61 |
Harvard Medical School
| 28 years |
Dennis Selkoe | M | 80 |
Harvard Medical School
| 24 years |
Bill Helman | M | 65 |
Harvard Medical School
| - |
Alfred Lewis Goldberg | M | 81 |
Harvard Medical School
| 55 years |
Neil L. Chayet | M | 85 |
Harvard Medical School
| - |
William Gerald Austen | M | 94 |
Harvard Medical School
| 50 years |
Lynne Zydowsky | M | 65 |
Harvard Medical School
| - |
Donald William Kufe | M | 79 |
Harvard Medical School
| - |
Laurie Glimcher | M | 72 |
Harvard Medical School
| - |
Samuel O. Thier | M | 86 |
Harvard Medical School
| - |
Peter J. Zimetbaum | M | 60 |
Harvard Medical School
| 18 years |
Freda Lewis-Hall | M | 69 |
Harvard Medical School
| - |
Troyen Brennan | M | 69 |
Harvard Medical School
| - |
Alan Garber | M | 68 |
Harvard Medical School
| - |
Joseph Loscalzo | M | 72 |
Harvard Medical School
| - |
David H. Sachs | M | 77 |
Harvard Medical School
| 33 years |
Raju S. Kucherlapati | M | 81 |
Harvard Medical School
| 23 years |
Lan Bo Chen | M | 80 |
Harvard Medical School
| 27 years |
George Demetri | M | 67 |
Harvard Medical School
| 36 years |
Elsie Tavaras | M | - |
Harvard Medical School
| - |
H. Thomas Aretz | M | - |
Harvard Medical School
| - |
Miles Shore | M | - |
Harvard Medical School
| - |
Timothy Springer | M | 76 |
Harvard Medical School
| 13 years |
Alfred Sandrock | M | 67 |
Harvard Medical School
| - |
Michael B. Brenner | M | - |
Harvard Medical School
| - |
Scott A. Shikora | M | - |
Harvard Medical School
| - |
Steven E. Shoelson | M | - |
Harvard Medical School
| - |
James Bradner | M | 52 |
Harvard Medical School
| - |
Mason W. Freeman | M | 73 |
Harvard Medical School
| - |
Fabrice Balavoine | M | - |
Harvard Medical School
| - |
Peter T. Lansbury | M | - |
Harvard Medical School
| - |
Robert Margolis | M | 77 |
Harvard Medical School
| - |
Donald Berwick | M | 77 |
Harvard Medical School
| - |
Jean-Pierre Kinet | M | 70 |
Harvard Medical School
| 29 years |
Leonard I. Zon | M | - |
Harvard Medical School
| - |
George Church | M | 69 |
Harvard Medical School
| 38 years |
William F. Crowley | M | - |
Harvard Medical School
| - |
Catherine McCormick Blair | F | - |
Harvard Medical School
| - |
Henry J. Aaron | M | - |
Harvard Medical School
| - |
Gregory Verdine | M | 65 |
Harvard Medical School
| 35 years |
David R. Elmaleh | M | 76 |
Harvard Medical School
| - |
Curtis L. Cetrulo | M | 54 |
Harvard Medical School
| 15 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Luk Vandenberghe
- Personal Network